Navigation Links
TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
Date:5/22/2008

SAN MARINO, Calif., May 22 /PRNewswire/ -- Epeius Biotechnologies announced today the promising results of an on-going United States-based Phase I/II study of Rexin-G for metastatic breast cancer that is refractory to conventional chemotherapy (J Clin Oncol 26:14509, 2008). This clinical trial employed intra-patient dose-escalations of Rexin-G given i.v. two to three times a week for 4 weeks, with doses ranging from 2 x 10e11 cfu to 6 x 10e11 cfu per week. The goal of the adaptive trial design is to confirm the over-all safety of Rexin-G and to determine the optimal dosing regimen for Rexin-G that would document the significant clinical benefits required to support a Phase II pivotal study.

The interim results of this Phase I/II study of targeted gene delivery in vivo are very encouraging -- intravenous infusions of Rexin-G demonstrated significant biological activity without toxicity in patients with rapidly progressive chemo-resistant breast cancer. Once the general safety of repeated infusions of Rexin-G was documented, the FDA approved across the board intra-patient dose-escalations in order to gain better tumor control. These escalating doses of Rexin-G were associated with stabilization of disease, using both RECIST and International PET criteria, significant reductions in CA 15.3 levels, a median progression-free survival of 6 months (RECIST) and a median over-all survival of greater than 7 months with all patients surviving at the 8-month follow-up period. No dose-limiting toxicity was observed, even at the higher doses of Rexin-G, thus confirming that repeated infusions of Rexin-G are safe and well-tolerated.

According to Dr. Erlinda M. Gordon, Medical Director of Epeius, "The importance of these dose-escalation studies -- which clearly establish safety before escalating to more potent tumoricidal levels -- is a primary concern in the development of a new genetic medicine like Rexin-G." Taken together with the results of previous studies, the current on-going Phase I/II study confirms the exemplary safety and therapeutic potential of Rexin-G in chemotherapy-resistant metastatic breast cancer.

For more information about Rexin-G, on-going clinical trials in the USA and abroad, and/or Epeius pathotropic (disease-seeking) gene delivery systems, please contact Dr. Erlinda M. Gordon at egordon@epeiusbiotech.com.
On the Web: http://www.epeiusbiotech.com.

*(LOGO 72dpi: Send2Press.com/mediaboom/08-0421-Epeius_72dpi.jpg)

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com


'/>"/>
SOURCE Epeius Biotechnologies
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)
2. Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine
3. Semafores PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma
4. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
5. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
6. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
7. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
8. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
9. ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
10. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
11. Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... International plc (NASDAQ: ENDP ) will announce its second-quarter ... senior management team will host a conference call and webcast before ... The dial-in number to access the call is U.S./ ... is 45397076. Please dial in 10 minutes prior to the scheduled ... of the call will be available from August 8, 2017 at ...
(Date:7/12/2017)... -- CarpalAID is a revolutionary new product that relieves painful carpal ... tunnel syndrome affects more than 8 million people a year. Women ... The common methods of treating CTS are painful surgery, the use ... gloves. ... CarpalAID is a clear patch worn on the palm of the ...
(Date:7/11/2017)... 11, 2017  Sysmex America, Inc., a leading ... equipment as well as middleware information systems technology, ... make quality assurance easier and more risk free ... known for the innovation that it delivers to ... quality assurance processes to a new level with ...
Breaking Medicine Technology:
(Date:7/26/2017)... BC (PRWEB) , ... July 26, 2017 , ... ... (the “Company” or “Isodiol”) a global cannabis innovator, specializing in the development of ... the period from April 1, 2017 to June 30, 2017. Iso International LLC ...
(Date:7/26/2017)... ... 26, 2017 , ... The number of adults 65 years or older is ... improve asthma control in the population are not well described. In a study published ... official journal of the American Academy of Allergy, Asthma & Immunology (AAAAI), researchers identified ...
(Date:7/25/2017)... ... July 25, 2017 , ... Creative Pharmacist and ... provide the Pharmacist eCare Plan to Computer-Rx pharmacies through the STRAND ... ability to develop the Pharmacist eCare Plan, a shared document detailing a patient’s ...
(Date:7/25/2017)... ... July 25, 2017 , ... Nautilus Hyosung ... States, today announced its partnership with financial technology company, Automated Transaction Delivery (ATD), ... the solution lies within Hyosung’s superior ATMs, assisted self-service devices and associated software. ...
(Date:7/25/2017)... ... 2017 , ... SignatureCare Emergency Center – South Austin is treating both adult ... day. , The Emergency Room opened early March, making it the ... now and things are running smoothly,” said Aaron Braun, SignatureCare Emergency Center’s Chief Medical ...
Breaking Medicine News(10 mins):